Topical vapocoolant spray in reducing the pain of intravenous cannulation in the emergency department: a randomised, single-blinded, placebo-controlled trial

A randomised controlled clinical trial to compare the efficacy of pressurised vapocoolant and water sprays in decreasing the pain of intravenous cannulation in emergency department patients.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000470493

Enrollment

200

Registered

2007-09-19

Start date

2007-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Vapocollant spray is used overseas to decrease the pain of intravenous cannulation. However, no randomised controlled trial has been reported to provide evidence for this.

Interventions

Two second spray of pressurised vapocoolant "COLD Spray" (butane, propane, pentane blend), from 12 cm, to the IV cannulation site. The alkane blend may vary with the batch and specific proportions of the three alkanes are not available

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to -2147483648 No limit

Healthy volunteers

Inclusion criteria

Emergency department patients, aged 18 years or more, requiring intravenous cannulation.

Exclusion criteria

Refusal to provide consent; Inability to provide informed consent (Non-English speaking, altered mental state, significant illness); Moderate to severe discomfort or pain; Diseases of the skin associated with cold intolerance (eg: Raynaud’s phenomenon); Known allergy to spray contents; Peripheral neuropathy; Parenteral analgesia in the previous 4 hours

Outcome results